Gourt > Health > Pharmacy > Drugs and Medications > A > Aripiprazole
Aripiprazole (produced by Bristol-Myers Squibb and sold as Abilify®) is the sixth and most recent of the atypical antipsychotic medications to be approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder.
Pharmacology
Aripiprazole possesses a novel mechanism of action when compared to the other FDA approved atypical antipsychotics (i.e. clozapine, olanzapine, quetiapine, ziprasidone, and risperidone). Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. Partial agonism at D2 receptors has been shown to modulate dopaminergic activity in areas where dopamine activity may be high or low, such as the mesolimbic and mesocortical areas of the schizophrenic brain, respectively. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.
Pharmacokinetics
More on [ Aripiprazole ]
Antipsychotics :: Drugs and Medications
@Pollytics Aripiprazole is nowhere near sedating enough to deal with your average Oz columnist
Dr_Tad (Tad Tietze) Fri, 06 Nov 2009 19:44:53 -0000
@Pollytics Aripiprazole is nowhere near sedating enough to deal with your average Oz columnist
Somebody give that bloke some political Aripiprazole
Pollytics (Possum Comitatus) Fri, 06 Nov 2009 14:05:10 -0000
Somebody give that bloke some political Aripiprazole
Abilify (Aripiprazole) - BMS - Official pharmaceutical site for this antipsychotic medication indicated for the treatment of schizophrenia.
Abilify Consumer Drug Info - Consumer FAQ in html format with a link to approved labeling in pdf format (requires Adobe Acrobat reader).
Meta Description: [ Consumer Information Sheet ]
Aripiprazole (Abilify) - Patient information sheet provided by the U.S. Food and Drug Administration Center for Drug Evaluation and Research. Includes FDA Alerts.
Aripiprazole (Abilify): A Novel Atypical Antipsychotic - Article describes this medication's mode of action, side effects, and some early experiences using it in children with psychotic or bipolar illness.
Meta Description: [ The Bipolar Child is a new book on early-onset bipolar disorder in children, written by authors Demitri and Janice Papolos who also wrote Overcoming Depression. ]
Bristol's Brightest Day, Blackest Night - Forbes article about the U.S. FDA approval of Abilify discusses this drug's pharmacology and stated advantages compared with other schizophrenia medications.
Meta Description: [ Abilify could be a breakthrough in treating schizophrenia, but Bristol's accounting is still a mess. ]
MedlinePlus: Aripiprazole - Features information about dosage, usage, warnings, and side effects.
Meta Description: [ Aripiprazole ]
MedlinePlus: Aripiprazole (Systemic) - Features information about dosage, usage, warnings, and side effects.
Meta Description: [ Aripiprazole(Systemic) ]
| Alert on Atypical Antipsychotics (June 2005) | |
